EcoDrugPlus

Sodium Voltage-Gated Channel Alpha Subunit 3

Ensembl ID : ENSBMSG00010012845
Gene Symbol: SCN3A
1 Cross references
133 Possible Orthologues:

Sodium Voltage-Gated Channel Alpha Subunit 4

Ensembl ID : ENSBMSG00010021817
Gene Symbol: SCN4A
1 Cross references
192 Possible Orthologues:

Sodium Voltage-Gated Channel Alpha Subunit 5

Ensembl ID : ENSBMSG00010017592
Gene Symbol: SCN5A
1 Cross references
94 Possible Orthologues:

Sodium Voltage-Gated Channel Alpha Subunit 7

Ensembl ID : ENSBMSG00010016677
Gene Symbol: SCN7A
1 Cross references
85 Possible Orthologues:

Sodium Voltage-Gated Channel Alpha Subunit 8

Ensembl ID : ENSBMSG00010006195
Gene Symbol: SCN8A
1 Cross references
276 Possible Orthologues:

Sodium Voltage-Gated Channel Alpha Subunit 9

Ensembl ID : ENSBMSG00010015385
Gene Symbol: SCN9A
1 Cross references
109 Possible Orthologues:

Solute Carrier Family 10 Member 2

Ensembl ID : ENSBMSG00010017257
Gene Symbol: SLC10A2
1 Cross references
211 Possible Orthologues:

Solute Carrier Family 18 Member A2

Ensembl ID : ENSBMSG00010013731
Gene Symbol: SLC18A2
1 Cross references
222 Possible Orthologues:

Solute Carrier Family 22 Member 6

Ensembl ID : ENSBMSG00010008894
Gene Symbol: SLC22A6
1 Cross references
495 Possible Orthologues:

Solute Carrier Family 22 Member 8

Ensembl ID : ENSBMSG00010008957
Gene Symbol: SLC22A8
1 Cross references
304 Possible Orthologues:

Solute Carrier Family 29 Member 1 (Augustine Blood Group)

Ensembl ID : ENSBMSG00010018936
Gene Symbol: SLC29A1
1 Cross references
280 Possible Orthologues:

Solute Carrier Family 5 Member 1

Ensembl ID : ENSBMSG00010011596
Gene Symbol: SLC5A1
1 Cross references
250 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).